Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$2.58 -0.8%	$2.16	$1.20 ▼ $6.75	$146.71M	2.71	1.56 million shs	472,335 shs
KALV KalVista Pharmaceuticals	$11.90 +1.0%	$12.39	$7.30 ▼ $15.50	$595.59M	-0.04	492,167 shs	338,543 shs
KROS Keros Therapeutics	$13.33 -0.6%	$14.00	$9.12 ▼ $72.37	$546.28M	1.26	865,079 shs	148,107 shs
TNGX Tango Therapeutics	$5.69 +0.7%	$3.16	$1.03 ▼ $12.02	$617.85M	1.63	1.59 million shs	620,177 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	0.00%	+9.79%	+3.61%	+84.29%	-41.89%
KALV KalVista Pharmaceuticals	0.00%	+4.29%	-13.77%	+11.11%	+1.54%
KROS Keros Therapeutics	0.00%	-1.19%	-11.78%	+33.57%	-68.39%
TNGX Tango Therapeutics	0.00%	+13.57%	+62.11%	+348.03%	-31.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BDTX Black Diamond Therapeutics	3.1408 of 5 stars	3.5	3.0	0.0	3.6	1.7	0.6
KALV KalVista Pharmaceuticals	4.1608 of 5 stars	3.6	1.0	4.4	2.4	2.5	0.6
KROS Keros Therapeutics	3.6248 of 5 stars	4.3	3.0	0.0	0.0	5.0	0.6
TNGX Tango Therapeutics	2.0032 of 5 stars	3.5	2.0	0.0	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDTX Black Diamond Therapeutics	3.00	Buy	$12.80	396.12% Upside
KALV KalVista Pharmaceuticals	3.13	Buy	$24.83	108.68% Upside
KROS Keros Therapeutics	2.50	Moderate Buy	$30.56	129.22% Upside
TNGX Tango Therapeutics	3.00	Buy	$12.20	114.41% Upside

Current Analyst Ratings Breakdown

Latest BDTX, KALV, TNGX, and KROS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$11.00
6/10/2025	KROS Keros Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$32.00 ➝ $18.00
5/30/2025	KROS Keros Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$15.00
5/12/2025	KROS Keros Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$41.00 ➝ $26.00
5/8/2025	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $25.00
4/14/2025	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/9/2025	KROS Keros Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$43.00 ➝ $25.00
4/8/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	$1.47 per share	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.86 per share	N/A
KROS Keros Therapeutics	$3.55M	152.53	N/A	N/A	$14.11 per share	0.94
TNGX Tango Therapeutics	$42.07M	14.66	N/A	N/A	$1.86 per share	3.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDTX Black Diamond Therapeutics	-$69.68M	$0.06	43.00	N/A	N/A	N/A	4.70%	3.47%	8/5/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$126.64M	-$3.72	N/A	N/A	N/A	N/A	-104.25%	-78.69%	7/10/2025 (Estimated)
KROS Keros Therapeutics	-$187.35M	-$0.18	N/A	N/A	N/A	1.96%	0.75%	0.69%	8/6/2025 (Estimated)
TNGX Tango Therapeutics	-$130.30M	-$1.22	N/A	N/A	N/A	-322.67%	-62.75%	-39.94%	8/6/2025 (Estimated)

Latest BDTX, KALV, TNGX, and KROS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	TNGX Tango Therapeutics	-$0.34	-$0.36	-$0.02	-$0.36	$6.73 million	$5.39 million
5/6/2025	Q1 2025	KROS Keros Therapeutics	-$0.01	$3.62	+$3.63	$3.62	$84.62 million	$211.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDTX Black Diamond Therapeutics	N/A	9.24	9.24
KALV KalVista Pharmaceuticals	N/A	10.44	10.44
KROS Keros Therapeutics	N/A	19.29	19.29
TNGX Tango Therapeutics	N/A	6.26	6.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDTX Black Diamond Therapeutics	95.47%
KALV KalVista Pharmaceuticals	N/A
KROS Keros Therapeutics	71.56%
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
BDTX Black Diamond Therapeutics	5.97%
KALV KalVista Pharmaceuticals	10.50%
KROS Keros Therapeutics	22.90%
TNGX Tango Therapeutics	7.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDTX Black Diamond Therapeutics	90	56.86 million	53.47 million	Optionable
KALV KalVista Pharmaceuticals	100	49.72 million	44.50 million	Optionable
KROS Keros Therapeutics	100	40.62 million	31.31 million	Optionable
TNGX Tango Therapeutics	90	108.39 million	100.26 million	Optionable

BDTX, KALV, TNGX, and KROS Headlines

Recent News About These Companies

HC Wainwright Issues Positive Estimate for TNGX Earnings

July 2, 2025 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $12.20 Consensus Target Price from Analysts

July 1, 2025 | americanbankingnews.com

Tango Therapeutics doses first patient in cancer drug combo trial

June 29, 2025 | uk.investing.com

Tango Therapeutics (NASDAQ:TNGX) Trading 6.5% Higher - Here's What Happened

June 29, 2025 | americanbankingnews.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Rating of "Buy" from Analysts

June 28, 2025 | marketbeat.com

Tango Therapeutics Shares Climb After First Patient Dosed in Pancreatic, Lung Cancer Trial

June 27, 2025 | marketwatch.com

Tango Therapeutics (NASDAQ:TNGX) Trading Up 6.5% - Should You Buy?

June 27, 2025 | marketbeat.com

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

June 27, 2025 | globenewswire.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 8.3% - Should You Sell?

June 25, 2025 | marketbeat.com

Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? - Nasdaq

June 25, 2025 | nasdaq.com

Exchange Traded Concepts LLC Purchases 47,901 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)

June 25, 2025 | marketbeat.com

Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?

June 23, 2025 | zacks.com

Tango Therapeutics (NASDAQ:TNGX) Shares Up 4.7% - What's Next?

June 17, 2025 | marketbeat.com

Tango Therapeutics’ SWOT analysis: stock poised for growth amid clinical trials

June 16, 2025 | investing.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 7.4% - Here's What Happened

June 13, 2025 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Shares Gap Down - Time to Sell?

June 12, 2025 | marketbeat.com

B. Riley Expects Higher Earnings for Tango Therapeutics

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Predicts TNGX FY2026 Earnings

June 11, 2025 | marketbeat.com

Q2 Earnings Forecast for TNGX Issued By B. Riley

June 11, 2025 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Trading Up 11.8% - Should You Buy?

June 10, 2025 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock Holdings Increased by Bank of America Corp DE

June 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX, KALV, TNGX, and KROS Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

$2.58 -0.02 (-0.77%)

Closing price 07/3/2025 03:42 PM Eastern

Extended Trading

$2.59 +0.01 (+0.39%)

As of 07/3/2025 04:58 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

KalVista Pharmaceuticals NASDAQ:KALV

$11.90 +0.12 (+1.02%)

Closing price 07/3/2025 03:53 PM Eastern

Extended Trading

$12.04 +0.14 (+1.21%)

As of 07/3/2025 04:58 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Keros Therapeutics NASDAQ:KROS

$13.33 -0.08 (-0.60%)

As of 07/3/2025 03:30 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Tango Therapeutics NASDAQ:TNGX

$5.69 +0.04 (+0.71%)

Closing price 07/3/2025 03:56 PM Eastern

Extended Trading

$5.69 0.00 (0.00%)

As of 07/3/2025 04:26 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time